title: Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
abstract: To determine whether the route of administration or the type of estrogen used in estrogen replacement therapy (ERT) is more important in avoiding effects on hepatic function, 24 postmenopausal women were studied before and at the end of 2 months of oral or percutaneous administration of the same estrogen, estradiol-17 beta (E2). The treatments studied were oral micronized E2, 2 mg/day (9 women); oral E2 valerate, 2 mg/day (5 women), and percutaneous E2, 3 mg/day (10 women). Specific plasma biological and biochemical markers of estrogenic action were evaluated, namely, E2, estrone (E1), LH, FSH, sex steroid binding protein (SBP), renin substrate, antithrombin activity, and lipoproteins (high density lipoprotein cholesterol, low density lipoprotein cholesterol, very low density lipoprotein triglycerides). Both oral and percutaneous administration of E2 increased plasma E2 levels up to midfollicular values and decreased LH and FSH levels into the same range. Oral administration of E2 led to substantial increases in plasma E1, SBP, renin substrate, and VLDL levels, whereas AT decreased significantly. Percutaneous administration of E2 led to a physiological plasma E1/E2 ratio and did not induce any change in hepatic proteins. These data suggest that the route of administration of E2 determines the biochemical response to ERT in postmenopausal women. SBP is the most sensitive marker of the liver action of estrogen, and triglycerides also are simple and useful markers for this effect. Percutaneous E2 therapy is an effective method of ERT, and has no measurable effects on hepatic markers of estrogen action.
authors.forename: B
authors.initials: B
authors.lastname: De Lignieres
authors.forename: A
authors.initials: A
authors.lastname: Basdevant
authors.forename: G
authors.initials: G
authors.lastname: Thomas
authors.forename: J C
authors.initials: JC
authors.lastname: Thalabard
authors.forename: C
authors.initials: C
authors.lastname: Mercier-Bodard
authors.forename: J
authors.initials: J
authors.lastname: Conard
authors.forename: T T
authors.initials: TT
authors.lastname: Guyene
authors.forename: N
authors.initials: N
authors.lastname: Mairon
authors.forename: P
authors.initials: P
authors.lastname: Corvol
authors.forename: B
authors.initials: B
authors.lastname: Guy-Grand
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000808:Angiotensinogen / Q000097:blood; D000991:Antithrombins / Q000378:metabolism; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism
chemical_list: D000991:Antithrombins; D008055:Lipids; D012738:Sex Hormone-Binding Globulin; D000808:Angiotensinogen; D004970:Estrone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone